Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Gesves – page 55

942 clinical trials in Gesves, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Gesves at a glance
942
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

942 trials in Gesves

Open in trial search

Study on BI 1819479 to Improve Lung Function in Patients with Idiopathic Pulmonary Fibrosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BI 1819479
  • Sponsor:Boehringer Ingelheim Espana S.A.

Title: Study of everolimus with hormone therapy in women with high-risk breast cancer (ER-positive, HER2-negative) who are disease-free after initial treatment

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Unicancer

Rectal cancer stage III+1

Not recruiting

Study of regorafenib and nivolumab with radiotherapy for patients with stage II-III rectal cancer before surgery

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Nivolumab
  • Sponsor:Institut Jules Bordet

Study Comparing Trastuzumab Deruxtecan with Chemotherapy for Patients with HER2-Low, Hormone Receptor Positive Breast Cancer After Endocrine Therapy Progression

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Fallopian tube cancer+2

Not recruiting

Study of Nemvaleukin Alfa and Pembrolizumab for Patients with Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Nemvaleukin Alfa
  • Sponsor:Mural Oncology Inc.

Plasma cell myeloma

Not recruiting

Study on Elranatamab and Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma After Prior Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Pfizer Inc.

Study on Axatilimab and Ruxolitinib for Patients with Newly Diagnosed Chronic Graft-Versus-Host Disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Axatilimab
  • Sponsor:Incyte Corp.

Breast cancer

Not recruiting

Study of Camizestrant and CDK4/6 Inhibitor for Patients with Advanced Breast Cancer with ESR1 Mutation

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

Encephalopathy neonatal+1

Not recruiting

Study on the Effect of Allopurinol and Hypothermia for Newborns with Hypoxic-Ischemic Encephalopathy

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Allopurinol Sodium
  • Sponsor:Universitaetsklinikum Tuebingen AöR

Pre-eclampsia

Not recruiting

Study on Low Dose Acetylsalicylic Acid to Prevent Preeclampsia in Pregnant Women After Frozen Embryo Transfer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Acetylsalicylic Acid
  • Sponsor:CHU De Liege

Breast cancer female

Not recruiting

Study on Chemotherapy and Hormone Therapy for Women Over 70 with ER-Positive, HER2-Negative Breast Cancer Using Cyclophosphamide and Drug Combination

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Unicancer

Study on Inupadenant, Carboplatin, and Pemetrexed for Adults with Metastatic Non-Small Cell Lung Cancer After Immunotherapy

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Inupadenant Hydrochloride
  • Sponsor:iTeos Belgium

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Gesves

What the registry says about research in the country

01 Respiratory Medicine

Innovative research focusing on chronic rhinosinusitis treatment, specifically targeting patients with nasal polyps. Clinical investigations are evaluating novel therapeutic approaches using monoclonal antibodies to improve patient outcomes.

  • Nasal Polyp Management
  • Anti-IL-33 Therapy
  • Rhinosinusitis Treatment

The trials aim to assess new therapeutic options for patients with inadequately controlled symptoms, focusing on reducing polyp size and alleviating nasal congestion.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.